

SUBSTITUTE FORM PTO-1449
(MODIFIED)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
06275/034001

SERIAL NO.
08/601,005

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

APPLICANT
Kjell Bäckström et al.

FILING DATE
March 1, 1996

GROUP
1615

(37 CFR 1.98(b))

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
7.0	AA	5 2 2 5 1 8 3	7/6/93	Purewal et al.	424	45	
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
2.0	AL	WO 91/11495	8/8/91	PCT WO				X
2.1	AM	O 518 600 A1	12/16/92	European Europe				
	AN							
	AO							
	AP							

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	AQ	
	AR	
	AS	

EXAMINER

BAAW

DATE CONSIDERED

9/22/98

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 06275/034001		SERIAL NO. 08/601,005		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b))				APPLICANT Kjell Backstrom et al.				
				FILING DATE March 1, 1996		GROUP		
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
P.17	AA	3 0 1 4 8 4 4	12/26/61	Thiel et al.	167	82		
	AB	3 6 3 2 7 4 3	01/04/72	Geller et al.	424	45		
	AC	4 2 3 2 0 0 2	11/04/80	Nogrady	424	45		
	AD	4 5 4 8 9 2 2	10/22/85	Carey et al.	514	4		
	AE	4 6 1 3 5 0 0	09/23/86	Suzuki et al.	429	85		
	AF	4 6 9 0 9 5 2	09/01/87	Kagatani et al.	514	808		
	AG	4 7 4 6 5 0 8	05/24/88	Carey et al.	424	88		
	AH	4 7 8 8 2 2 1	11/29/88	Kagatani et al.	514	808		
	AI	4 7 9 4 0 0 0	12/27/88	Ecanow	424	457		
	AJ	4 8 4 7 2 9 8	07/11/89	Alexander et al.	514	565		
P.13	AK	4 8 4 9 4 0 5	07/18/89	Ecanow	514	3		
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION								
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
P.13	AL	837,465	15 JUN 60	GB				
	AM	WO 92/08446	29 MAY 92	PCT WO				
	AN	WO 91/04011	04 APR 91	PCT WO				
	AO	0 499 344 A2	27 NOV 89	EP Europe				
	AP	WO 91/16038	31 OCT 91	PCT WO				
	AQ	WO 91/14422	03 OCT 91	PCT WO				
	AR	26 20 446.6	08 MAY 76	Germany				
	AS	0 200 383	07 APR 86	EP Europe				
	AT	0 360 340	18 SEP 89	EP Europe				
P.17	AU	8007820-7	17 NOV 86	Sweden				
EXAMINER BAWA				DATE CONSIDERED 9/22/98				
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 06275/034001		SERIAL NO. 08/601,005		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b))				APPLICANT Kjell Backstrom et al.				
				FILING DATE March 1, 1996		GROUP		
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
P-13	CA	5 2 0 2 1 2 9	04/13/93	Samejima et al.	424	489		
	CB	5 2 8 4 6 5 6	02/08/94	Platz et al.	424	435		
	CC	5 3 0 6 4 8 3	04/26/94	Mautone	424	45		
	CD	5 3 4 8 7 3 0	09/20/94	Greenleaf et al.	424	45		
	CE	5 3 5 4 5 6 2	10/11/94	Platz et al.	424	489		
	CF	5 3 6 4 8 3 8	11/15/94	Rubsamen	514	3		
	CG	5 5 0 6 2 0 3	04/09/96	Backstrom et al.	514	4		
	CH	5 5 1 4 6 7 0	05/07/96	Friedman et al.	514	2		
P-13	CI	5 5 1 8 9 9 8	05/21/96	Backstrom et al.	514	3		
	CJ							
	CK							
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION								
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
P-13	CL	76 36431	03 DEC 76	France				
	CM	0 130 550	27 JUN 84	EE Europe				
	CN	0 133 252	19 JUL 84	EP Europe				
	CO	WO 91/11495	08 AUG 91	PCT WO				
	CP	0 518 600 A1	08 JUN 92	EP Europe				
	CQ	9400371-2	04 FEB 94	Sweden				
P-13	CR	9302198-8	16 MAY 94	Sweden				
	CS							
EXAMINER BAWA				DATE CONSIDERED 9/22/98				
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

Substitute Disclosure Form (PTO-1449)

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
06275/034001SERIAL NO.
08/601,005INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)APPLICANT
Kjell Backstrom et al.FILING DATE
March 1, 1996

GROUP

(37 CFR 1.98(b))

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

7-17	DA	Allenby et al., "The absorption of Insulin Across the Respiratory Tract of the Guinea-Pig" The Aerosol Society, Fourth Annual Conference, University of Surrey, Apr. 9-11, 1990.
	DB	Aungst et al., "Comparison of the effects of various transmucosal absorption promoters of buccal insulin delivery" Int. J. Pharm. (Netherlands) 53(3):227-235, 1989. (abstract)
	DC	Bjork, "Starch Microspheres as a Nasal Delivery System for Drugs" ACTA Universitatis Upsaliensis 103, 1993.
	DD	Bjork et al., "Degradable starch microspheres as a nasal delivery system for insulin" Int. J. Pharm 47: 233-238, 1988.
	DE	Chandler et al., "Nasal absorption in rats. II Effect of enhancers on insulin absorption and nasal histology" Int. J. Pharm 76:61-70, 1991.
	DF	Cutie et al., "The Role of Dispersing Agents in Inhalation and Intranasal Aerosol Suspensions" Aerosol Age, pp. 52-54, 1985.
	DG	Damasy et al., "Intranasal Insulin" Diabetes Res. and Clin. Pract. 5:S163, 1988.
	DH	Edman et al., "Routes of Delivery: Case Studies: Nasal Delivery of Peptide Drugs" Advanced Drug Del. Rev. 8:165-177, 1992.
	DI	Gordon et al., "Nasal absorption of insulin: Enhancement by hydrophobic bile salts" Proc. Natl. Acad. Sci. 32:7419-7423, 1985.
	DJ	Hirai et al., "Effect of Surfactants on the Nasal Absorption of Insulin in Rats" Int. J. Pharm. 9:165-172, 1981.
	DK	Igawa et al., "Effect of Absorption Promoters in Intranasal Administration of Human Fibroblast Interferon.." Chem Pharm. Bull. 37:418-421, 1989.
7-17	DL	Komada et al., "Intratracheal Delivery of Peptide and Protein Agents: Absorption from Solution and Dry Powder by Rat Lung" J. Pharm. Sciences 83:863, 1994.

EXAMINER

B AWA

DATE CONSIDERED

9/22/98

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
06275/034001SERIAL NO.
08/601,005INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)APPLICANT
Kjell Backstrom et al.FILING DATE
March 1, 1996

GROUP

(37 CFR 1.98(b))

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

7.17	EA	Lee et al., "Mucosal Penetration Enhancers for Facilitation of Peptide and Protein Drug Absorption" Crit. Rev. Therapeutic Drug Carrier Systems 8(2):91-192, 1991.
	EB	Lee et al., "Intranasal Bioavailability of Insulin Powder Formulations:..." J. Pharm. Sciences 80(8):725, 1991.
	EC	Mishima et al., "Studies on the Promoting Effects of Medium Chain Fatty Acid Salts on the Nasal Absorption..." J. Pharma. Dyn. 10:624-631, 1987.
	ED	Morita et al., "Effects of Various Absorption Promoters on Pulmonary Absorption of Drugs..." Biol. Pharm. Bull. 16:269-262, 1993.
	EE	Moses et al., "Insulin Administered Intranasally as an Insulin-Bile Salt Aerosol" Diabetes 32:1040, 1983.
	EF	Olanoff et al., "Method to Enhance Intranasal Peptide Delivery" American Chemical Society Symposium, Lee & Good, eds., New York, April 13-18, 1986.
	EG	Pontiroli et al., "Nasal administration of glucagon and human calcitonin to healthy subjects: a comparison of powders..." Eur. J. Clin. Pharmacol. 37:427-430, 1989.
	EH	SanGiovanni, "Just how practical is aerosolized nasal insulin" Spray Tech. & Marketing 2(1):16-19, 1992.
	EI	Schipper et al., "Nasal Insulin Delivery with Dimethyl-B-Cyclodextrin as an Absorption Enhancer in Rabbits..." Pharm. Res. 10:682, 1993.
	EJ	Touitou et al., "Targeted Enteral Delivery of Insulin to Rats" Int. J. Pharm. (AMST) 30:95-100, 1986.
	EK	Wearley, "Recent Progress in Protein and Peptide Delivery by Noninvasive Routes" Crit. Rev. in Therapeutic Drug Carrier Systems 8(4):331-394, 1991.
	EL	Wigley et al., "Insulin Across Respiratory Mucosae by Aerosol Delivery" Diabetes 20(8):552, 1971.
	EM	Yoshida et al., "Absorption of Insulin Delivered to Rabbit Trachea Using Aerosol Dosage Form" J. of Pharm. Sciences 68:670, 1979.
7.17	EN	Zinman, "The physiologic replacement of insulin" Medical Intelligence: Drug Therapy 321:363, 1989.

EXAMINER

ISAWA

DATE CONSIDERED

9/22/98

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)